Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide once weekly versus liraglutide once daily added to oral antidiabetic drugs in adults with type 2 diabetes
2016-004965-22Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Semaglutide add-on arm with Liraglutide add-on arm (2 arms). Primary endpoint: Change in HbA1c. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-004965-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004965-22.